Use of Cyclodextrins in Anticancer Photodynamic Therapy Treatment

Molecules

Céline Frochot¹  Zahraa Youssef¹  Francis Baros¹  Amina Ben Mihoub²  Ludivine Larue²  Régis Vanderesse²  Albert Moussaron²  Samir Acherar²  Ludovic Colombeau² 

[1] Laboratoire Réactions et Génie des Procédés, Université de Lorraine, CNRS, LRGP, F-54000 Nancy, France;Laboratoire de Chimie Phusique Macromoléculaire, Université de Lorraine, CNRS, LCPM, F-54000 Nancy, France;

关键词: cylodextrin;    photosensitizer;    photodynamic therapy;    cancer;    inclusion complex;    conjugate;    nanoassembly;    nanoparticle;    porphyrinoid;    fullerene;   

DOI  :  10.3390/molecules23081936

来源: DOAJ

【 摘 要 】

Photodynamic therapy (PDT) is mainly used to destroy cancerous cells; it combines the action of three components: a photoactivatable molecule or photosensitizer (PS), the light of an appropriate wavelength, and naturally occurring molecular oxygen. After light excitation of the PS, the excited PS then reacts with molecular oxygen to produce reactive oxygen species (ROS), leading to cellular damage. One of the drawbacks of PSs is their lack of solubility in water and body tissue fluids, thereby causing low bioavailability, drug-delivery efficiency, therapeutic efficacy, and ROS production. To improve the water-solubility and/or drug delivery of PSs, using cyclodextrins (CDs) is an interesting strategy. This review describes the in vitro or/and in vivo use of natural and derived CDs to improve antitumoral PDT efficiency in aqueous media. To achieve these goals, three types of binding modes of PSs with CDs are developed: non-covalent CD–PS inclusion complexes, covalent CD–PS conjugates, and CD–PS nanoassemblies. This review is divided into three parts: (1) non-covalent CD-PS inclusion complexes, covalent CD–PS conjugates, and CD–PS nanoassemblies, (2) incorporating CD–PS systems into hybrid nanoparticles (NPs) using up-converting or other types of NPs, and (3) CDs with fullerenes as PSs.

【 授权许可】

Unknown